MedPath

Problem Solving Treatment for Diabetes in Individuals With Poor Diabetes Control

Not Applicable
Active, not recruiting
Conditions
Diabetes Mellitus, Type 2
Interventions
Behavioral: Problem Solving Treatment for Diabetes
Behavioral: Attention Control Group
Registration Number
NCT05651490
Lead Sponsor
Singapore Eye Research Institute
Brief Summary

The goal of this randomised controlled trial is to test a cognitive-behavioural intervention, Problem Solving Treatment for Diabetes (PST-D) in patients with type 2 diabetes. The main questions it aims to answer are:

* To evaluate the clinical effectiveness of PST-D compared with the attention control group.

* To determine the impact of PST-D on patient-centred, behavioural, and psychosocial outcomes.

* To identify independent factors associated with an improvement in HbA1c and reductions in incidence and progression diabetic retinopathy, diabetic neuropathy, diabetic peripheral neuropathy, and visual impairment at 18-month follow-up in both groups; and determine if these factors mediate the associations between the PST-D intervention with the above outcomes.

* To quantify the incremental cost-effectiveness of PST-D compared with the attention control group at 18-month follow-up.

* To understand participants' views, experiences, and opinions about PST-D; and the barriers and facilitators to program completion.

Participants will complete blood tests, ocular examinations, and a series of questionnaires at baseline, 6-month, 12-month, and 18-month follow-up. Participants will also complete the intervention/ control group sessions conducted over the phone, video call, or face-to-face depending on the participant's preference.

Researchers will compare the intervention group against the attention control group to determine the effectiveness of PST-D on improving clinical, patient-centred, behavioural, and psychosocial outcomes.

Detailed Description

Assuming the recent rise in obesity prevalence persists, the lifetime risk of diabetes in Singapore will almost double by 2050. Poorly controlled diabetes leads to various diabetes-related complications which may consequently require costly lifelong treatment and have a profound impact on patients' quality of life.

Based on a previous trial on problem solving therapy in people with diabetic retinopathy and significant levels of distress, the investigators have designed a cognitive-behavioural intervention which aims to teach individuals skills to cope with and solve problems related to diabetes self-management. This novel intervention will be carried out at one tertiary hospital in Singapore, with the option for interested community-dwelling individuals with diabetes to participate, to facilitate its implementation and transition to the real world setting to assist patients with diabetes.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
106
Inclusion Criteria
  • Patients with type 2 diabetes and at least 1 recent reading of suboptimal glycaemic control (HbA1c ≥7.0%)
  • Able to speak English and/or Mandarin
  • Singapore citizens or those with Singapore permanent residency status
  • Aged 21 years and above
  • No cognitive impairment, as assessed using the 6-item Cognitive Impairment Test (6CIT)
  • Adequate hearing with/without hearing aids to respond to normal conversation
  • Consent to participate in the sessions if randomised to the PST-D treatment arm
Exclusion Criteria
  • Have hearing or cognitive impairment compromising consent or study procedures
  • All recent HbA1c readings are <7.0%
  • Uncontactable or unwilling/unable to participate in all the PST-D sessions if randomised to the PST-D group

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention Group (PST-D)Problem Solving Treatment for DiabetesParticipants in the intervention group will receive usual care comprising of routine follow-up checks from their hospitals on top of the intervention (PST-D). The intervention consists of one introductory session, up to eight weekly treatment sessions, and three monthly maintenance sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.
Attention control groupAttention Control GroupThe participants in the control group will receive usual care comprising of routine follow-up checks from their hospitals. They will also receive one introductory session and up to eight weekly treatment sessions; these are individual sessions of approximately 30 to 45 minutes each and will be conducted over the phone, video call, or face-to-face depending on the participant's preference.
Primary Outcome Measures
NameTimeMethod
Change in HbA1c over 18 monthsBaseline, 6-month, 12-month, 18-month

Blood test

Secondary Outcome Measures
NameTimeMethod
Incidence and progression of diabetic retinopathyBaseline, 6-month, 12-month, 18-month

Grading of digital retinal photographs and spectral-domain optical coherence tomography scans

Incidence and progression of diabetic peripheral neuropathyBaseline, 6-month, 12-month, 18-month

Semmes-Weinstein monofilament examination (SWME) results

Change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides over 18 monthsBaseline, 6-month, 12-month, 18-month

Blood tests

Incidence and progression of diabetic nephropathyBaseline, 6-month, 12-month, 18-month

Blood tests results of epidermal growth factor receptor from serum creatinine and estimated using the CKD-EPI equation

Incidence and progression of distance visual impairmentBaseline, 6-month, 12-month, 18-month

Pinhole visual acuity values

Change in diabetes self-care activities over 18 monthsBaseline, 6-month, 12-month, 18-month

Diabetes Self-management Questionnaire

Minimum value: 0 Maximum value: 12

Higher values indicate more effective self-care.

Change in diabetes self-efficacy over 18 monthsBaseline, 6-month, 12-month, 18-month

Perceived Diabetes Self-management scale.

Minimum value: 8 Maximum value: 40

Higher scores indicate more confidence in self-managing one's diabetes.

Change in problem-focused coping self-efficacy over 18 monthsBaseline, 6-month, 12-month, 18-month

Problem-Focusing subscale from Coping Self-Efficacy Scale

Minimum value: 0 Maximum value: 120

Higher scores indicate higher level of problem-focused coping self-efficacy.

Cost-effectiveness of PST-DBaseline, 6-month, 12-month, 18-month

EQ-5D-5L

There are five dimensions in the EQ-5D-5L descriptive system - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses to the five dimensions are used to calculate an index score ranging from -0.59 for the worst health state to 1.00 for perfect health. A score of 0 represents death and a negative score indicates a state worse than death.

Change in medication taking behaviour over 18 monthsBaseline, 6-month, 12-month, 18-month

Domains of Subjective Extent of Nonadherence

It comprises two domains - the extent of and reasons for medication non-adherence over the past 7 days.

For the Extent of Non-Adherence domain, the overall score is calculated by the average score of the three items, with higher scores indicating greater levels of non-adherence (Minimum value: 0; Maximum value: 4).

There are 18 items in the Reasons for Non-Adherence domain which stand on their own as descriptors. The reasons scale is a causal indicator model and higher scores indicate greater endorsement of each reason for non-adherence (Minimum value: 0; Maximum value: 4).

Change in diabetes-related quality of life over 18 monthsBaseline, 6-month, 12-month, 18-month

Asian Diabetes Quality of Life

Minimum value: 18 (English version); 15 (Chinese version) Maximum value: 105 (English version); 90 (Chinese version)

Higher scores indicate better quality of life.

Trial Locations

Locations (1)

Singapore Eye Research Institute

🇸🇬

Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath